Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / May / Enzyme Evolution
Manufacture Small Molecules

Enzyme Evolution

By mimicking natural evolution of enzymes, researchers are creating biocatalysts for reactions unheard of in nature

By Charlotte Barker 05/05/2015 1 min read

Share

Engineered cytochrome P450 enzymes can perform chemical reactions valuable to the pharmaceutical community. Credit: Frances H. Arnold

We have covered the power of metabolic engineering – designing enzymes to build chemicals – previously in The Medicine Maker (tmm.txp.tp/0115/rebirth). Now, the latest research from scientists at Caltech demonstrates that by using nature’s driving force – evolution – it is possible to induce existing enzymes to take on entirely new jobs (1).

The group started with the observation that nature often creates new enzymes by a process of gradual evolution from an existing enzyme. They reasoned that recapitulating this process in a test tube would likely have more success than trying to engineer a new enzyme from scratch. Starting with a bacterial cytochrome P450, the team induced mutations in the active site of the molecule and selected for the variants with most activity in aziridination of olefins, a reaction of interest to the pharmaceutical industry, but not usually found in nature. By this process of directed evolution, the group succeeded in producing the first example of enzyme-catalyzed olefin aziridination. The authors write, “These results demonstrate the critical role of protein engineering in optimizing non-natural reactivity and suggest that the well-known plasticity of the P450 active site can be leveraged to target progressively more challenging non-natural reactions.” In contrast to rational protein design, directed evolution does not require an in-depth understanding of how protein structure impacts on function, instead relying on the same principles as selective breeding. Previous work by the Caltech group, led by bioengineering pioneer Frances Arnold, has generated enzymes able to withstand high temperatures and produce massively increased yields, useful for industrial synthesis pf pharmaceuticals, biofuels and more. The authors of the current study believe that there are likely to be many more enzymes capable of taking on entirely new functions, concluding “This new aziridination biocatalyst is likely just one of many new catalysts that will be discovered when researchers start systematically exploring the new functions that existing enzymes can take on. Exploiting the catalytic promiscuity of natural enzymes combined with evolutionary optimization will enable us to greatly expand the reaction space of genetically encoded biocatalysts.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. C.C. Farwell et al., “Enantioselective Enzyme-Catalyzed Aziridination Enabled by Active-Site Evolution of a Cytochrome P450”, ACS Cent. Sci., DOI: 10.1021/acscentsci.5b00056 (2015).

About the Author(s)

Charlotte Barker

As an Editor at Texere, I’m working closely with our audience to create vibrant, engaging content that reflects the hard work and passion that goes into bringing new medicines to market. I got my start in biomedical publishing as a commissioning editor for healthcare journals and have spent my career covering everything from early-stage research to clinical medicine, so I know my way around. And I can’t think of a more interesting, challenging or important area to be working in.

More Articles by Charlotte Barker

False

Advertisement

Recommended

False

Related Content

The Final Frontier?
Small Molecules
The Final Frontier?

December 1, 2014

0 min read

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

Calculate – Don’t Estimate – Drug Development Costs
Small Molecules
Calculate – Don’t Estimate – Drug Development Costs

December 1, 2014

0 min read

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right? And how can we accurately determine the true costs?

Electrifying R&D Acceleration
Small Molecules Analytical Science
Electrifying R&D Acceleration

December 2, 2014

0 min read

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings...

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.